MIRA PHARMACEUTICALS, INC. 8-K

What Happened

• MIRA Pharmaceuticals, Inc. announced on June 3, 2026 that it entered into an Amended and Restated Exclusive License Agreement with MIRALOGX LLC. The agreement grants MIRA worldwide exclusive rights to certain intellectual property covering its MIRA-55 and SKNY-1 development programs, including the rights to develop, manufacture, use, sell, commercialize and sublicense products covered by that IP. The company issued a press release about the agreement on June 4, 2026 (filed as Exhibit 99.1).

Key Details

• Agreement date: June 3, 2026; press release dated June 4, 2026.
• Scope: worldwide exclusive rights to IP for MIRA-55 and SKNY-1, plus enforcement and sublicensing rights.
• Economics: the amended agreement “does not materially modify” the parties’ previously disclosed core economic terms.
• Filing: the amended license will be filed as an exhibit to MIRA’s next periodic report; press release attached as Exhibit 99.1 in the 8-K.

Why It Matters

• For investors, this confirms MIRA holds exclusive global rights to the intellectual property for two of its development programs, which is material to the company’s ability to advance, partner, or commercialize those assets. Because the filing states the amendment does not materially change prior economic terms, the transaction likely does not alter previously disclosed financial obligations or revenue-sharing arrangements. Watch for the full license text (to be filed) and future updates on development or commercialization milestones.